FDA-Drug2026-09-09Class IIPROCESSING DEFECT

Baxter CARDENE IV nicardipine injection recalled for manufacturing quality deviations

OTHERNationwide distributionDrugs

What this means

Baxter Healthcare has recalled specific lots of CARDENE IV (nicardipine hydrochloride) injection due to deviations from manufacturing quality standards. The affected lots were distributed in the United States, Puerto Rico, and Chile.

  • If your healthcare facility has received lots NC177818 (expires 12/31/2026) or NC188869 (expires 12/31/2027), stop using them immediately.
  • Contact Baxter Healthcare or your supplier for return or replacement instructions.
  • Consult your healthcare provider if you have questions about alternative treatments.
The agency's original wording
Hazard

CGMP Deviations

Intended for
Adults
Illnesses reported
None reported
Sold states
US Nationwide; Puerto Rico; and Chile.
Affected count
N/A
Manufactured in
1 Baxter Pkwy, N/A, Deerfield, IL, United States
Products
CARDENE IV (Nicardipine Hydrochloride) in 0.83% Sodium Chloride Injection, 40 mg in 200 mL (0.2 mg/mL) in GALAXY Single-Dose Container, Manufactured and Marketed by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 43066-016-10.

Official notice

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0813-2026

More Baxter recalls

Want us to check the next one for you?

We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.

Free · One email a week · Unsubscribe anytime